Dare Bioscience, Inc. stock is down -9.23% since 30 days ago. The next earnings date is Mar 28, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 9 December’s closed higher than November. 100% of analysts rate it a buy.
Daré Bioscience, Inc. develops therapies in the areas of contraception, fertility, and sexual and vaginal health. Its product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive.